(Q51044379)

English

Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis.

scientific article published in August 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23615046

0 references

Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23615046

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

author name string

Qi Xu

1

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23615046

An Tao Xu

2

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23615046

Ming Ming Zhu

3

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23615046

Jin Lu Tong

4

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23615046

Xi Tao Xu

5

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23615046

Zhi Hua Ran

6

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23615046

publication date

1 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23615046

Journal of Digestive Diseases

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23615046

14

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23615046

8

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23615046

409-416

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23615046

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Epidermal growth factor receptor (EGFR) signaling in cancer

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Systemic therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12063

21 January 2018

Identifiers

10.1111/1751-2980.12063

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23615046

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23615046

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51044379&oldid=1501494553"